Aller au contenu

Compounded GLP-1 Recall and 'Research Use' Retatrutide Put Unapproved Weight-Loss Drugs Under Scrutiny

23 octobre 2026 · 22 min

Notes de l’épisode

Unapproved GLP-1 drugs are under pressure from several directions. Compounding pharmacy Apothecary Pharma voluntarily recalled 22 lots of compounded tirzepatide, the active ingredient in Zepbound and Mounjaro, citing "lack of assurance of sterility," and FDA classified the recall as Class II. A bipartisan group of senators led by Sen. Jim Banks wrote to the acting FDA commissioner on October 14, 2026, urging a crackdown on vendors using "for research use only" labels to sell retatrutide, Eli Lilly's investigational drug that is not FDA-approved, and citing a 265% rise in poisonings tied to illicit retatrutide reported by America's Poison Centers. CBS News reported that FDA received two adverse-event reports of deaths linked to products sold as retatrutide; the reports are unverified and do not prove the products caused the deaths. We also walk through FDA's own warnings: compounded drugs are not FDA-approved, retatrutide cannot be used in compounding, and FDA has flagged quality problems at overseas ingredient suppliers. We explain how compounded, counterfeit and "research use only" products differ from FDA-approved medicines, and what regulators, lawmakers and drugmakers are doing about them. Sources: - FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (updated Oct 1, 2026): https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss - Sen. Jim Banks press release and senators' letter to FDA (Oct 15, 2026): https://www.banks.senate.gov/news/press-releases/banks-urges-fda-to-crack-down-on-illicit-research-use-only-drugs/ - CBS News, reported deaths and bootleg retatrutide: https://www.cbsnews.com/news/deaths-reported-fda-bootleg-reta-weight-loss-drug/ - BioPharma Dive, Apothecary Pharma compounded tirzepatide recall (Oct 22, 2026): https://www.biopharmadive.com/news/glp1-obesity-drug-recall-apothecary-tirzepatide-zepbound/833712/ - USA TODAY, compounded GLP-1 recall and FDA actions (Oct 20, 2026): https://www.usatoday.com/story/money/personal-finance/healthcare/2026/10/20/fda-targets-copycat-glp-1-weight-loss-drugs/92343423007/ Cover photo: laboratory at the FDA White Oak campus, Building 64 (U.S. Food and Drug Administration, public domain, via Wikimedia Commons; cropped). This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.com

Tous les épisodes de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Paramètres

Affichage

Langue

Détermine les stations affichées en premier sur la page d’accueil.

Historique

Les stations et épisodes écoutés récemment et tes dernières recherches sont seulement enregistrés dans ce navigateur.

Notifications

Un court message quand un podcast que tu suis publie un nouvel épisode. Désactive un podcast précis avec la cloche sur sa page.

Compte

Enregistrez vos favoris – dans l’app et sur le site.

Raccourcis clavier

/
Ouvrir la recherche
Espace
Lecture ou pause
← →
Dans le lecteur : 15 s en arrière, 30 s en avant (épisodes) · dans une rangée : tuile suivante
↑ ↓
Dans une rangée : cible dans la tuile
Début / Fin
Dans une rangée : première ou dernière tuile
Esc
Fermer la fenêtre ou le menu
?
Cet aperçu
En cours de lecture

Voir la station

À suivre

    Ajoutez des épisodes avec « À suivre » – ils seront lus après l'épisode en cours.